Clinical Trials Logo

2019-nCoV clinical trials

View clinical trials related to 2019-nCoV.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT04356508 Not yet recruiting - COVID-19 Clinical Trials

COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1

Start date: April 14, 2020
Phase: Phase 2
Study type: Interventional

This is an open-label, controlled, single-centre pilot study of nivolumab in adult patients with COVID-19. This clinical study aims to evaluate efficacy of anti-PD1 antibody in relation to viral clearance and its safety.

NCT ID: NCT04270383 Not yet recruiting - 2019-nCoV Clinical Trials

Clinical Characteristics and Long-term Prognosis of 2019-nCoV Infection in Children

Start date: February 15, 2020
Phase:
Study type: Observational

The study is designed to clarify the clinical characteristics, risk factors and long-term prognosis of children with 2019-nCoV infection in China.

NCT ID: NCT04264858 Not yet recruiting - 2019-nCoV Clinical Trials

Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients

Start date: March 17, 2020
Phase: N/A
Study type: Interventional

The new coronavirus pneumonia is an acute infectious pneumonia. The pathogen is a previously unknown new coronavirus, namely 2019 new coronavirus (2019 novel coronavirus, 2019 nCoV). However, there is no specific anti-viral drug. It has been found that the specific antibodies against virus antigen are produced after these patients were cured, which could block the infection of 2019 nCoV on the host cells. At present, immunoadsorption is the most direct, rapid and effective method to separate immunoglobulin from the cured patients. Therefore, the study aims to prepare the immunoglobulin from 2019-ncov pneumonia cured patients, evaluate the efficacy and safety of the immunoglobulin in 2019-ncov pneumonia cured patients on the treatment of acute severe 2019-ncov pneumonia, and provide a new strategy for the treatment of 2019-ncov pneumonia.

NCT ID: NCT04261426 Not yet recruiting - 2019-nCoV Clinical Trials

The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia

Start date: February 10, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

In this single-center, randomized, open-label, controlled study, the investigators will evaluate the efficacy and safety of Intravenous Immunoglobulin (IVIG) in combination with standard care for severe 2019 novel coronavirus (2019-nCoV) pneumonia.